The historical rank and industry rank for Hims & Hers Health's ROE % or its related term are showing as below:
MEX:HIMS'
s ROE % Range Over the Past 10 Years
Min: -114.69 Med: -7.18 Max: 30.71
Current: -2.47
During the past 7 years, Hims & Hers Health's highest ROE % was 30.71%. The lowest was -114.69%. And the median was -7.18%.
MEX:HIMS's ROE % is ranked worse than 72.22% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs MEX:HIMS: -2.47
Hims & Hers Health (MEX:HIMS) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Hims & Hers Health ROE % Related Terms
Hims & Hers Health ROE % Historical Data
* Premium members only.
The historical data trend for Hims & Hers Health's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hims & Hers Health's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hims & Hers Health ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hims & Hers Health's ROE % distribution charts can be found below:
* The bar in red indicates where Hims & Hers Health's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Hims & Hers Health (MEX:HIMS) has a ROE % of -74.72% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Hims & Hers Health and its competitors. According to the industry distribution chart, Hims & Hers Health ranks #676 out of 936 companies in the Drug Manufacturers industry, placing it in the top 72.2%.
Is Hims & Hers Health's ROE % too high?
Hims & Hers Health's current ROE % is -74.72%. Based on the distribution chart, Hims & Hers Health ranks #676 out of 936 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hims & Hers Health has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hims & Hers Health's ROE % compare to LNTH and LQDA?
According to the Drug Manufacturers industry distribution chart, Hims & Hers Health ranks #676 out of 936 companies for ROE %. This places Hims & Hers Health in the lower half of its industry. The industry median ROE % is 5.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Hims & Hers Health and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hims & Hers Health's current ROE % is -74.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hims & Hers Health stock overvalued right now?
Based on GuruFocus' analysis, Hims & Hers Health (MEX:HIMS) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN672.61, compared to a current price of MXN591.55 — trading 12.1% below its estimated fair value. The current ROE % is -74.72%. Hims & Hers Health's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Hims & Hers Health (MEX:HIMS), the current ROE % is -74.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hims & Hers Health (MEX:HIMS) Overvalued in 2026?
Based on GuruFocus' analysis, Hims & Hers Health stock appears to be undervalued.
The current stock price of MXN591.55 is trading 12.1% below its estimated GF Value™ of MXN672.61.
GuruFocus considers Hims & Hers Health to be Modestly Undervalued.
Key valuation signals for MEX:HIMS:
ROE %: -74.72%
GF Value™: MXN672.61 vs. price of MXN591.55 (12.1% below fair value)
No single metric tells the full story. See the MEX:HIMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
58GF Score
Get the complete analysis for MEX:HIMS
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:HIMS has been successfully added to your 
